3-32997333-C-T
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_000404.4(GLB1):c.1746G>A(p.Trp582*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000186 in 1,612,912 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000404.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GLB1 | ENST00000307363.10 | c.1746G>A | p.Trp582* | stop_gained | Exon 16 of 16 | 1 | NM_000404.4 | ENSP00000306920.4 | ||
GLB1 | ENST00000307377.12 | c.1353G>A | p.Trp451* | stop_gained | Exon 13 of 13 | 1 | ENSP00000305920.8 | |||
GLB1 | ENST00000399402.7 | c.1656G>A | p.Trp552* | stop_gained | Exon 16 of 16 | 2 | ENSP00000382333.2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152158Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000403 AC: 1AN: 247986Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 134748
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1460754Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 726656
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152158Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74310
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Observed in a patient reported to have infantile GM1-gangliosidosis who also possessed second GLB1 variant (Higaki et al., 2011); Nonsense variant predicted to result in protein truncation, as the last 96 amino acids are lost, and other loss-of-function variants have been reported downstream in HGMD; Published functional studies demonstrate a damaging effect (HIgaki et al., 2011); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 23337983, 20175788, 21520340, 10744681) -
GM1 gangliosidosis;C0086652:Mucopolysaccharidosis, MPS-IV-B Pathogenic:1
Experimental studies have shown that this premature translational stop signal affects GLB1 function (PMID: 20175788). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg590 amino acid residue in GLB1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 16941474, 17309651, 17664528, 23430803). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. ClinVar contains an entry for this variant (Variation ID: 557709). This premature translational stop signal has been observed in individual(s) with GM1-gangliosidosis (PMID: 21520340). This variant is present in population databases (rs778375259, gnomAD 0.007%). This sequence change creates a premature translational stop signal (p.Trp582*) in the GLB1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 96 amino acid(s) of the GLB1 protein. -
Mucopolysaccharidosis, MPS-IV-B;C0268271:Infantile GM1 gangliosidosis;C0268272:GM1 gangliosidosis type 2;C0268273:GM1 gangliosidosis type 3 Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at